FDA: Weight Loss Drug Possibly Linked to Cancer
Lorcaserin may potentially increase the risk of cancer, according to results from a clinical trial assessing the safety of the weight loss agent.
Lorcaserin may potentially increase the risk of cancer, according to results from a clinical trial assessing the safety of the weight loss agent.
Although most cases of lymphedema are mild or moderate, obesity and overweight are common factors in women who experience severe lymphedema and HADS-anxiety after breast cancer surgery.
Among breast cancer and prostate cancer patients, scores for distress higher for obese than nonobese.
But no correlation seen for overweight or obesity with early relapse in cohort of Mexican children with ALL.
Using data from the CPS-II, researchers determined a link between higher BMI in adults younger than 50 years and risk of pancreatic cancer.
In men, overweight and even higher normal weight is associated with an increased risk of future pancreatic cancer.
An increased body mass index (BMI) may negatively affect disease progression in patients with T1G3 non-muscle-invasive bladder cancer, according to study data.
A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.
Weight loss associated with bariatric surgery could reduce risk of hormone-related cancers, but an increased risk for colorectal cancer was seen in patients who underwent gastric bypass.
Researchers report on a study to determine the relationship between BMI and risk for breast cancer among younger women, particularly those 18 to 24 years old.